{"id":"hlx03","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HLX03 targets programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the PD-L1/PD-1 interaction that normally suppresses T-cell activation. By blocking this immune checkpoint, the drug allows cytotoxic T lymphocytes to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-L1 inhibitors and is designed to enhance anti-tumor immunity across multiple cancer types.","oneSentence":"HLX03 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:48.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT03316781","phase":"PHASE3","title":"Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-10-27","conditions":"Plaque Psoriasis","enrollment":262},{"nctId":"NCT03357939","phase":"PHASE1","title":"Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-01-12","conditions":"Immune System Disorder","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["adalimumab biosimilar"],"phase":"phase_3","status":"active","brandName":"HLX03","genericName":"HLX03","companyName":"Shanghai Henlius Biotech","companyId":"shanghai-henlius-biotech","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HLX03 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Other solid tumors (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}